Q32 Bio (QTTB) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed SIGA Technologies (SIGA) over the past year, gaining 157.4% versus a loss of 60.4%. Over five years, SIGA leads with a -53.9% price change compared with -92.5% for QTTB. Q32 Bio is the larger company by market cap ($248.3 million vs $235.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QTTB | SIGA |
|---|---|---|
| Share price | $8.34 | $3.28 |
| Market cap | $248.28M | $235.67M |
| 1-day change | +3.09% | 0.00% |
| YTD return | +151.20% | -46.32% |
| 1-year return | +157.41% | -60.39% |
| 5-year return | -92.53% | -53.87% |
| P/E ratio (TTM) | 2.65 | — |
| Forward P/E | — | 3.04 |
| EPS (TTM) | $3.15 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.57 | $8.55 |
| 52-week low | $1.91 | $2.83 |
| Distance from 52-week high | -64.62% | -61.64% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +374.82% | — |
| Average volume | 1.38M | 726.75K |
| Shares outstanding | 29.77M | 71.85M |
| Employees | 22 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed SIGA by 217.8 percentage points over the past year.
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
QTTB vs SIGA FAQ
Which is bigger, Q32 Bio or SIGA Technologies?
Q32 Bio (QTTB) is larger, with a market capitalization of $248.28M compared with $235.67M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, QTTB or SIGA?
QTTB returned +157.41% over the past 12 months, compared with -60.39% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Q32 Bio and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.